JP5048520B2 - Ｅ１活性化酵素の阻害剤 - Google Patents
Ｅ１活性化酵素の阻害剤 Download PDFInfo
- Publication number
- JP5048520B2 JP5048520B2 JP2007554355A JP2007554355A JP5048520B2 JP 5048520 B2 JP5048520 B2 JP 5048520B2 JP 2007554355 A JP2007554355 A JP 2007554355A JP 2007554355 A JP2007554355 A JP 2007554355A JP 5048520 B2 JP5048520 B2 JP 5048520B2
- Authority
- JP
- Japan
- Prior art keywords
- aliphatic
- optionally substituted
- ring
- hydrogen
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 O[C@](C1)[C@@](COS=O)O[C@]1N1C=NC2C(*Cc(cc3)ccc3F)=NC=NC12 Chemical compound O[C@](C1)[C@@](COS=O)O[C@]1N1C=NC2C(*Cc(cc3)ccc3F)=NC=NC12 0.000 description 16
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N C1Cc2ccccc2C1 Chemical compound C1Cc2ccccc2C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- VWDODFKGOZMCTI-GUEGTDDRSA-N CC(C(NCN1[C@@H]([C@@H]2O)O[C@H](COS(N)(=O)=O)[C@H]2O)=C1/N=C\N)C#Cc1ccccc1C(F)(F)F Chemical compound CC(C(NCN1[C@@H]([C@@H]2O)O[C@H](COS(N)(=O)=O)[C@H]2O)=C1/N=C\N)C#Cc1ccccc1C(F)(F)F VWDODFKGOZMCTI-GUEGTDDRSA-N 0.000 description 1
- POCFHRJJQIVGLV-FOFQZHAKSA-N CC(C([n]1c(C(C)CC=CN=C2C#Cc(c(F)c3)ccc3F)c2nc1)O[C@@H]1COS(N)(=O)=O)C1=O Chemical compound CC(C([n]1c(C(C)CC=CN=C2C#Cc(c(F)c3)ccc3F)c2nc1)O[C@@H]1COS(N)(=O)=O)C1=O POCFHRJJQIVGLV-FOFQZHAKSA-N 0.000 description 1
- RIYVYWAOFUYBMZ-DJLDLDEBSA-N CC(C)(O)O[C@@H](C1)[C@@H](C=O)O[C@H]1[n]1c(ncnc2Cl)c2nc1 Chemical compound CC(C)(O)O[C@@H](C1)[C@@H](C=O)O[C@H]1[n]1c(ncnc2Cl)c2nc1 RIYVYWAOFUYBMZ-DJLDLDEBSA-N 0.000 description 1
- NCVIFDCAYBPSAO-DJLDLDEBSA-N CC(C)(O)O[C@@H](C1)[C@@H](CO)O[C@H]1[n]1c(ncnc2Cl)c2nc1 Chemical compound CC(C)(O)O[C@@H](C1)[C@@H](CO)O[C@H]1[n]1c(ncnc2Cl)c2nc1 NCVIFDCAYBPSAO-DJLDLDEBSA-N 0.000 description 1
- SLESENNTTYPGMK-VBARCJAFSA-N CC(C)Cc1c2nc[n](C([C@@H]3O)O[C@H](CO)[C@H]3O)c2ncn1 Chemical compound CC(C)Cc1c2nc[n](C([C@@H]3O)O[C@H](CO)[C@H]3O)c2ncn1 SLESENNTTYPGMK-VBARCJAFSA-N 0.000 description 1
- BAUSBZSGKFYEPW-WQLSENKSSA-N CC([n]1c2ncnc(N)c2nc1)O/C(/COS(N)(=C)=O)=C(/O)\OC Chemical compound CC([n]1c2ncnc(N)c2nc1)O/C(/COS(N)(=C)=O)=C(/O)\OC BAUSBZSGKFYEPW-WQLSENKSSA-N 0.000 description 1
- UAEPNZWRGJTJPN-UHFFFAOYSA-N CC1CCCCC1 Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 1
- CLYBBBJDSNHABS-DASYDHELSA-N CCOS(CC[C@H](C[C@H]1OC(C)(C)O)OC1[n]1c(ncnc2Cl)c2nc1)=O Chemical compound CCOS(CC[C@H](C[C@H]1OC(C)(C)O)OC1[n]1c(ncnc2Cl)c2nc1)=O CLYBBBJDSNHABS-DASYDHELSA-N 0.000 description 1
- URLNUQODDDRUJL-HAWKEBCRSA-N CN(C[C@H]([C@H](C1F)O)O[C@H]1[n]1c2ncnc(NC3c4ccccc4CC3)c2nc1)S=O Chemical compound CN(C[C@H]([C@H](C1F)O)O[C@H]1[n]1c2ncnc(NC3c4ccccc4CC3)c2nc1)S=O URLNUQODDDRUJL-HAWKEBCRSA-N 0.000 description 1
- ZFRWMDKURWAVCL-PGJBUIMWSA-N NS(NC[C@@H](CC[C@]1(N(C=NC23)C2=NC=N[C@@H]3NC(CC2)C3=C2C=CCC3)O)[C@H]1O)(=O)=O Chemical compound NS(NC[C@@H](CC[C@]1(N(C=NC23)C2=NC=N[C@@H]3NC(CC2)C3=C2C=CCC3)O)[C@H]1O)(=O)=O ZFRWMDKURWAVCL-PGJBUIMWSA-N 0.000 description 1
- CJGCRJFCNMVMJJ-QVDUIBETSA-N NS(OC[C@@H](C[C@H]([C@@H]1O)[n]2c3ncnc(C#Cc(cc4)ccc4Cl)c3nc2)[C@H]1O)(=O)=O Chemical compound NS(OC[C@@H](C[C@H]([C@@H]1O)[n]2c3ncnc(C#Cc(cc4)ccc4Cl)c3nc2)[C@H]1O)(=O)=O CJGCRJFCNMVMJJ-QVDUIBETSA-N 0.000 description 1
- WGRMKJOMYRKALZ-ARFHVFGLSA-N O[C@@H](C1)[C@@H](COS=O)O[C@H]1[n]1c2ncnc(C#Cc3ccccc3)c2nc1 Chemical compound O[C@@H](C1)[C@@H](COS=O)O[C@H]1[n]1c2ncnc(C#Cc3ccccc3)c2nc1 WGRMKJOMYRKALZ-ARFHVFGLSA-N 0.000 description 1
- HWRAGHXGTZTWIO-YNTRSHHASA-N O[C@H](C(COS=O)O[C@H]1N2C=NC3C(NCc4ccc5OCOc5c4)=NC=NC23)[C@H]1O Chemical compound O[C@H](C(COS=O)O[C@H]1N2C=NC3C(NCc4ccc5OCOc5c4)=NC=NC23)[C@H]1O HWRAGHXGTZTWIO-YNTRSHHASA-N 0.000 description 1
- VKTDDMRAUSOGSU-XNIJJKJLSA-N O[C@H]([C@@H](COS=O)O[C@H]1[n]2c3ncnc(NCCN4CCCC4)c3nc2)[C@H]1O Chemical compound O[C@H]([C@@H](COS=O)O[C@H]1[n]2c3ncnc(NCCN4CCCC4)c3nc2)[C@H]1O VKTDDMRAUSOGSU-XNIJJKJLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/048—Pyridine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65043305P | 2005-02-04 | 2005-02-04 | |
| US60/650,433 | 2005-02-04 | ||
| PCT/US2006/004637 WO2006084281A1 (en) | 2005-02-04 | 2006-02-02 | Inhibitors of e1 activating enzymes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008530027A JP2008530027A (ja) | 2008-08-07 |
| JP2008530027A5 JP2008530027A5 (enExample) | 2008-10-02 |
| JP5048520B2 true JP5048520B2 (ja) | 2012-10-17 |
Family
ID=36602517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007554355A Expired - Fee Related JP5048520B2 (ja) | 2005-02-04 | 2006-02-02 | Ｅ１活性化酵素の阻害剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US7951810B2 (enExample) |
| EP (1) | EP1848718B1 (enExample) |
| JP (1) | JP5048520B2 (enExample) |
| AU (1) | AU2006210422B2 (enExample) |
| CA (1) | CA2596424C (enExample) |
| CY (1) | CY1113166T1 (enExample) |
| DK (1) | DK1848718T3 (enExample) |
| ES (1) | ES2390803T3 (enExample) |
| HR (1) | HRP20120847T1 (enExample) |
| ME (1) | ME02012B (enExample) |
| PL (1) | PL1848718T3 (enExample) |
| PT (1) | PT1848718E (enExample) |
| RS (1) | RS52458B (enExample) |
| SI (1) | SI1848718T1 (enExample) |
| WO (1) | WO2006084281A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013103941A (ja) * | 2006-02-02 | 2013-05-30 | Millennium Pharmaceuticals Inc | Ｅ１活性化酵素の阻害剤 |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0500785D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| US20090220515A1 (en) * | 2006-02-13 | 2009-09-03 | Mount Sinai School Of Medicine | Treatment and prevention of renal disease |
| GB0607953D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607948D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607944D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607950D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| HRP20120494T1 (hr) | 2006-04-21 | 2012-08-31 | Novartis Ag | Derivati purina za uporabu kao agonista adenozin a2a receptora |
| GB0607945D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| EP1889846A1 (en) | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
| US8008307B2 (en) | 2006-08-08 | 2011-08-30 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of E1 activating enzymes |
| ME02789B (me) | 2006-08-08 | 2011-06-30 | Millennium Pharm Inc | Jedinjenja heteroarila korisna kao inhibitori e1 aktivirajućih enzima |
| EP1903044A1 (en) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
| CL2007002994A1 (es) * | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| JP2010508835A (ja) * | 2006-11-10 | 2010-03-25 | ノバルティス アーゲー | シクロペンテンジオールモノアセテート誘導体 |
| US7897737B2 (en) | 2006-12-05 | 2011-03-01 | Lasergen, Inc. | 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing |
| JP2010516254A (ja) | 2007-01-18 | 2010-05-20 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ユビキチンに対する新規活性化および転移カスケード |
| EP2540727B1 (en) * | 2007-08-02 | 2018-07-25 | Millennium Pharmaceuticals, Inc. | Sulfamoylating reagent |
| AU2013204618B2 (en) * | 2007-08-02 | 2015-11-05 | Takeda Pharmaceutical Company Limited | Process for the synthesis of E1 activating enzyme inhibitors |
| KR20100068286A (ko) * | 2007-10-17 | 2010-06-22 | 노파르티스 아게 | 아데노신 ａ1 수용체 리간드로서의 퓨린 유도체 |
| US8648085B2 (en) | 2007-11-30 | 2014-02-11 | Boehringer Ingelheim International Gmbh | 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| AU2009257369B2 (en) | 2008-06-11 | 2015-03-26 | Agilent Technologies, Inc. | Nucleotides and nucleosides and methods for their use in DNA sequencing |
| CN102143965A (zh) | 2008-09-08 | 2011-08-03 | 贝林格尔.英格海姆国际有限公司 | 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途 |
| JP2012503651A (ja) * | 2008-09-26 | 2012-02-09 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | ３−デアザネプラノシン誘導体 |
| UY32531A (es) | 2009-03-31 | 2010-10-29 | Boehringer Ingelheim Int | Nuevos compuestos para el tratamiento de trastornos del snc |
| EP2430026A1 (en) | 2009-05-14 | 2012-03-21 | Millennium Pharmaceuticals, Inc. | Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate |
| AR077859A1 (es) | 2009-08-12 | 2011-09-28 | Boehringer Ingelheim Int | Compuestos para el tratamiento de trastornos del snc |
| BR112013003097B1 (pt) | 2010-08-12 | 2021-03-16 | Boehringer Ingelheim International Gmbh | 6-cicloalquil-pirazolopirimidinonas e composição farmacêutica |
| CN103391939B (zh) | 2010-12-03 | 2016-03-09 | Epizyme股份有限公司 | 作为表观遗传酶调节剂的经取代的嘌呤和7-氮杂嘌呤化合物 |
| AU2011341441A1 (en) | 2010-12-03 | 2013-06-20 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
| EP2646454B1 (en) | 2010-12-03 | 2015-07-08 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| US20130040971A1 (en) | 2011-02-14 | 2013-02-14 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders |
| US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
| WO2012158789A2 (en) | 2011-05-17 | 2012-11-22 | St. Jude Children's Research Hospital | Methods and compositions for inhibiting neddylation of proteins |
| MY166889A (en) | 2011-08-24 | 2018-07-24 | Millennium Pharm Inc | Inhibitors of nedd8-activating enzyme |
| US20150030601A1 (en) * | 2011-10-07 | 2015-01-29 | Millennium Pharmaceuticals, Inc. | E1 enzyme mutants and uses thereof |
| CA2862580A1 (en) | 2011-10-28 | 2013-05-02 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to nae inhibitors |
| PL2773360T3 (pl) | 2011-11-03 | 2018-09-28 | Millennium Pharmaceuticals, Inc. | Podawanie inhibitora enzymu aktywującego NEDD8 i środka hipometylującego |
| KR102072041B1 (ko) | 2011-12-22 | 2020-01-31 | 앨리오스 바이오파마 인크. | 치환된 뉴클레오사이드, 뉴클레오타이드 및 그의 유사체 |
| UA116534C2 (uk) | 2012-02-17 | 2018-04-10 | Мілленніум Фармасьютікалз, Інк. | Піразолопіримідинілові інгібітори убіквітинактивуючого ферменту |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| WO2013188881A1 (en) * | 2012-06-15 | 2013-12-19 | President And Fellows Of Harvard College | Compounds, compositions and methods for treating or preventing neurodegenerative disorders |
| CN104684559A (zh) * | 2012-08-03 | 2015-06-03 | 米伦纽姆医药公司 | 针对Uba6的吲哚取代的吡咯并嘧啶基抑制剂 |
| WO2014026198A1 (en) | 2012-08-10 | 2014-02-13 | Epizyme, Inc. | Inhibitors of protein methyltransferase dot1l and methods of use thereof |
| EP2892536B1 (en) | 2012-09-06 | 2019-12-18 | Epizyme, Inc. | Method of treating leukemia |
| US10662477B2 (en) | 2012-10-01 | 2020-05-26 | Millennium Pharmaceuticals, Inc. | Biomarkers and methods to predict response to inhibitors and uses thereof |
| JP2016507496A (ja) | 2012-12-21 | 2016-03-10 | ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． | ブロモドメイン阻害剤としての新規複素環式化合物 |
| AU2014214561C1 (en) * | 2013-02-11 | 2019-01-17 | Mitokinin, Inc. | Compositions and methods for treating neurodegenerative diseases |
| WO2014152566A2 (en) | 2013-03-15 | 2014-09-25 | Epizyme, Inc. | Methods of synthesizing substituted purine compounds |
| WO2014145576A2 (en) | 2013-03-15 | 2014-09-18 | Northwestern University | Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer |
| CN105407973A (zh) | 2013-05-14 | 2016-03-16 | 米伦纽姆医药公司 | Nedd8活化酶抑制剂及化学治疗剂的投与 |
| KR102307566B1 (ko) | 2013-06-21 | 2021-10-05 | 제니쓰 에피제네틱스 리미티드 | 신규한 바이사이클릭 브로모도메인 억제제 |
| CN105473581B (zh) | 2013-06-21 | 2019-04-23 | 齐尼思表观遗传学有限公司 | 作为溴结构域抑制剂的新取代的双环化合物 |
| WO2015002994A2 (en) | 2013-07-02 | 2015-01-08 | Millennium Pharmaceuticals, Inc. | Heteroaryl compounds useful as inhibitors of sumo activating enzyme |
| CA2919948C (en) | 2013-07-31 | 2020-07-21 | Zenith Epigenetics Corp. | Novel quinazolinones as bromodomain inhibitors |
| ES2919024T3 (es) | 2014-02-11 | 2022-07-21 | Mitokinin Inc | Composiciones y procedimientos que utilizan las mismas para el tratamiento de enfermedades neurodegenerativas y mitocondriales |
| CN106661031B (zh) * | 2014-06-24 | 2019-07-23 | 大鹏药品工业株式会社 | 吡咯并嘧啶化合物或其盐、含有其的药物组合物及应用 |
| BR112016030787B1 (pt) | 2014-07-01 | 2022-12-20 | Takeda Pharmaceutical Company Limited | Entidade química, composição farmacêutica e seu uso |
| HK1245246A1 (zh) | 2014-12-01 | 2018-08-24 | 恒翼生物医药科技(上海)有限公司 | 作为溴域抑制剂的取代吡啶酮 |
| US10179125B2 (en) | 2014-12-01 | 2019-01-15 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| WO2016092375A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Corp. | Substituted heterocycles as bromodomain inhibitors |
| CN107406438B (zh) | 2014-12-17 | 2021-05-14 | 恒翼生物医药科技(上海)有限公司 | 溴结构域的抑制剂 |
| CN114702495A (zh) | 2015-11-20 | 2022-07-05 | 福马治疗有限公司 | 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮 |
| TWI623316B (zh) * | 2015-12-22 | 2018-05-11 | Taiho Pharmaceutical Co Ltd | Antitumor effect enhancer derived from pyrrolopyrimidine compound |
| CN106008394B (zh) * | 2016-05-23 | 2018-12-04 | 中国人民解放军第二军医大学 | 巯基苯并噻唑酰胺类化合物及其制备与作为药物的用途 |
| CN106854208B (zh) * | 2016-11-25 | 2019-04-09 | 成都柏睿泰生物科技有限公司 | 肿瘤抑制剂mln4924的合成方法 |
| WO2018213258A1 (en) * | 2017-05-15 | 2018-11-22 | Millennium Pharmaceuticals, Inc. | Treatment of merlin-deficient tumors using nae inhibitors |
| WO2018237145A1 (en) | 2017-06-21 | 2018-12-27 | Mitokinin, Inc. | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease |
| JP2020534331A (ja) * | 2017-09-21 | 2020-11-26 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | （（１ｓ，２ｓ，４ｒ）−４−｛４−［（１ｓ）−２，３−ジヒドロ−１ｈ−インデン−１−イルアミノ］−７ｈ−ピロロ［２，３−ｄ］ピリミジン−７−イル｝−２−ヒドロキシシクロペンチル）メチルスルファメートの共結晶形態、その製剤及び使用 |
| WO2019109016A1 (en) | 2017-12-01 | 2019-06-06 | Millennium Pharmaceuticals, Inc. | Biomarkers and methods for treatment with nae inhibitors |
| CN110218179B (zh) * | 2018-03-02 | 2020-08-04 | 新发药业有限公司 | 一种4-氨基-2-氯-3-硝基吡啶的制备方法 |
| AU2019301697A1 (en) | 2018-07-13 | 2021-01-07 | Il-2Rx, Inc. | Compounds, compositions, methods, and uses for treating cancer and immunological disorders |
| US12435088B2 (en) | 2018-12-21 | 2025-10-07 | Memorial Sloan-Kettering Cancer Center | Salicyl-adenosinemonosulfamate analogs and uses thereof |
| JP2022522534A (ja) | 2019-04-02 | 2022-04-19 | アリゴス セラピューティクス インコーポレイテッド | Ｐｒｍｔ５を標的にする化合物 |
| CN112079836B (zh) * | 2019-06-13 | 2022-12-13 | 中国科学院上海药物研究所 | 三唑并嘧啶类化合物及其盐、组合物和应用 |
| EP4319763A4 (en) * | 2021-04-09 | 2025-06-11 | Emory University | MODIFIED NUCLEOSIDES AND NUCLEOTIDE ANALOGUES AS ANTIVIRAL AGENT FOR CORONAVIRUS AND OTHER VIRUSES |
| WO2025059029A1 (en) * | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Methods of treating vexas syndrome |
| WO2025073926A1 (en) * | 2023-10-05 | 2025-04-10 | Københavns Universitet | An inhibitor of sumo e1-enzyme for use in tissue regeneration |
| CN117466963A (zh) * | 2023-11-08 | 2024-01-30 | 湖南大学 | 一种羟甲基的保护及脱保护方法 |
| CN117466965A (zh) * | 2023-11-08 | 2024-01-30 | 湖南大学 | 一种合成碱基序列的方法 |
| KR20250075265A (ko) * | 2023-11-21 | 2025-05-28 | 한국화학연구원 | Use1 활성을 억제하는 화합물 유도체, 및 이를 포함하는 암 예방 또는 치료용 약학 조성물 |
| WO2026015820A1 (en) * | 2024-07-12 | 2026-01-15 | Sobi, Inc. | Methods of treating vexas |
| CN120737113B (zh) * | 2025-09-03 | 2025-11-21 | 湖北师范大学 | 一种三唑并哒嗪类化合物区域选择性c3-h炔基化的方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3622561A (en) * | 1969-08-18 | 1971-11-23 | Univ Utah | Nucleoside sugar esters of sulfamic acid and method for preparation of the same |
| JPS62108897A (ja) | 1985-11-05 | 1987-05-20 | Rikagaku Kenkyusho | アスカマイシン誘導体及びその合成法並びに制癌剤 |
| GB8826205D0 (en) | 1988-11-09 | 1988-12-14 | Wellcome Found | Heterocyclic compounds |
| GB8826539D0 (en) * | 1988-11-14 | 1988-12-21 | Shell Int Research | Nitromethylene compounds their preparation & their use as pesticides |
| JPH0398593A (ja) * | 1989-09-12 | 1991-04-24 | Meiji Seika Kaisha Ltd | 抗生物質５’―ｏ―スルファモイルツベルサイジンの製造法およびその用途 |
| US5864033A (en) | 1989-09-15 | 1999-01-26 | Metabasis Therapeutics, Inc. | Adenosine kinase inhibitors |
| US5726302A (en) | 1989-09-15 | 1998-03-10 | Gensia Inc. | Water soluble adenosine kinase inhibitors |
| US5763596A (en) | 1989-09-15 | 1998-06-09 | Metabasis Therapeutics, Inc. | C-4' modified adenosine kinase inhibitors |
| US5721356A (en) | 1989-09-15 | 1998-02-24 | Gensia, Inc. | Orally active adenosine kinase inhibitors |
| US5674998A (en) | 1989-09-15 | 1997-10-07 | Gensia Inc. | C-4' modified adenosine kinase inhibitors |
| GB9325809D0 (en) | 1993-12-17 | 1994-02-23 | Zeneca Ltd | Herbicidal composition |
| GB9325810D0 (en) | 1993-12-17 | 1994-02-23 | Zeneca Ltd | Herbicidal composition |
| US6210917B1 (en) | 1993-12-29 | 2001-04-03 | The Regents Of The University Of California | Method for suppressing multiple drug resistance in cancer cells |
| US5767097A (en) | 1996-01-23 | 1998-06-16 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
| US5824657A (en) | 1997-03-18 | 1998-10-20 | Cubist Pharmaceuticals, Inc. | Aminoacyl sulfamides for the treatment of hyperproliferative disorders |
| US6734283B1 (en) | 1997-12-19 | 2004-05-11 | Millennium Pharmaceuticals, Inc. | Human proteins responsible for NEDD8 activation and conjugation |
| JPH11228446A (ja) | 1998-02-16 | 1999-08-24 | Mitsubishi Chemical Corp | 抗マラリア剤 |
| JPH11228422A (ja) | 1998-02-16 | 1999-08-24 | Mitsubishi Chemical Corp | 抗マラリア剤 |
| US20030109550A1 (en) * | 2001-09-19 | 2003-06-12 | Michael Clare | Substituted indazole compounds for the treatment of inflammation |
| ATE466581T1 (de) | 2001-12-07 | 2010-05-15 | Vertex Pharma | Verbindungen auf pyrimidin-basis als gsk-3-hemmer |
| EP1651595A2 (en) | 2003-05-30 | 2006-05-03 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| US20050282818A1 (en) * | 2004-06-22 | 2005-12-22 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
-
2006
- 2006-02-02 WO PCT/US2006/004637 patent/WO2006084281A1/en not_active Ceased
- 2006-02-02 EP EP06734691A patent/EP1848718B1/en not_active Expired - Lifetime
- 2006-02-02 ES ES06734691T patent/ES2390803T3/es not_active Expired - Lifetime
- 2006-02-02 US US11/346,469 patent/US7951810B2/en active Active
- 2006-02-02 SI SI200631462T patent/SI1848718T1/sl unknown
- 2006-02-02 HR HRP20120847TT patent/HRP20120847T1/hr unknown
- 2006-02-02 PT PT06734691T patent/PT1848718E/pt unknown
- 2006-02-02 ME MEP-2012-452A patent/ME02012B/me unknown
- 2006-02-02 RS RS20120452A patent/RS52458B/sr unknown
- 2006-02-02 PL PL06734691T patent/PL1848718T3/pl unknown
- 2006-02-02 DK DK06734691.6T patent/DK1848718T3/da active
- 2006-02-02 CA CA2596424A patent/CA2596424C/en not_active Expired - Fee Related
- 2006-02-02 AU AU2006210422A patent/AU2006210422B2/en not_active Ceased
- 2006-02-02 JP JP2007554355A patent/JP5048520B2/ja not_active Expired - Fee Related
-
2011
- 2011-02-11 US US13/025,621 patent/US20110136834A1/en not_active Abandoned
-
2012
- 2012-10-02 CY CY20121100911T patent/CY1113166T1/el unknown
-
2013
- 2013-05-23 US US13/901,006 patent/US20140256668A9/en not_active Abandoned
-
2014
- 2014-12-23 US US14/581,128 patent/US20170073367A9/en not_active Abandoned
-
2017
- 2017-07-10 US US15/645,685 patent/US20180086785A1/en not_active Abandoned
-
2020
- 2020-04-22 US US16/855,863 patent/US20210070798A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013103941A (ja) * | 2006-02-02 | 2013-05-30 | Millennium Pharmaceuticals Inc | Ｅ１活性化酵素の阻害剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20170073367A9 (en) | 2017-03-16 |
| HK1113363A1 (en) | 2008-10-03 |
| AU2006210422B2 (en) | 2012-09-13 |
| CY1113166T1 (el) | 2016-04-13 |
| PL1848718T3 (pl) | 2012-12-31 |
| EP1848718B1 (en) | 2012-08-01 |
| ES2390803T3 (es) | 2012-11-16 |
| US20210070798A1 (en) | 2021-03-11 |
| PT1848718E (pt) | 2012-10-11 |
| ME02012B (me) | 2013-02-28 |
| DK1848718T3 (da) | 2012-08-27 |
| SI1848718T1 (sl) | 2012-12-31 |
| US20130338094A1 (en) | 2013-12-19 |
| US20060189636A1 (en) | 2006-08-24 |
| WO2006084281A1 (en) | 2006-08-10 |
| RS52458B (sr) | 2013-02-28 |
| US7951810B2 (en) | 2011-05-31 |
| EP1848718A1 (en) | 2007-10-31 |
| US20160194348A1 (en) | 2016-07-07 |
| US20140256668A9 (en) | 2014-09-11 |
| AU2006210422A1 (en) | 2006-08-10 |
| CA2596424C (en) | 2016-03-29 |
| US20180086785A1 (en) | 2018-03-29 |
| HRP20120847T1 (hr) | 2012-11-30 |
| CA2596424A1 (en) | 2006-08-10 |
| JP2008530027A (ja) | 2008-08-07 |
| US20110136834A1 (en) | 2011-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7951810B2 (en) | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes | |
| ES2390921T3 (es) | Inhibidores de la enzima activadora E1 | |
| JP5906297B2 (ja) | Ｅ１活性化酵素のインヒビターとして有用なヘテロアリール化合物 | |
| HK1113363B (en) | Inhibitors of e1 activating enzymes | |
| HK1124609B (en) | Inhibitors of e1 activating enzyme | |
| HK1166308B (en) | Inhibitors of e1 activating enzymes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080813 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080813 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110624 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110629 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110921 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110929 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111021 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111028 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111122 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111213 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120312 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120319 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120412 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120419 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120511 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120518 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120612 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120705 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120719 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150727 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5048520 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| LAPS | Cancellation because of no payment of annual fees |